Evidence map›Paper›PMID 30038146›Full record

ArticleIndian journal of ophthalmology2018

The protective effect of simvastatin against ultraviolet B-induced corneal endothelial cell death.

Yi-Ru Ho, Chih-Hung Lin, Chan-Yen Kuo

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Yi-Ru HoDepartment of Medical Research and Development, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
Chih-Hung LinDepartment of Internal Medicine, Cathay General Hospital, Taipei, Taiwan.
Chan-Yen KuoDepartment of Biomedical Sciences and Engineering, Graduate Institute of Systems Biology and Bioinformatics, National Central University, Chungli; Department of Ophthalmology, Hsin Sheng Junior College of Medical Care and Management, Longtan, Taiwan.
Cathay General Hospital · TWChang Bing Show Chwan Memorial Hospital · TWHsin Sheng College of Medical Care and Management · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Excessive ultraviolet B (UVB) exposure causing corneal endothelium injury, including apoptosis, is a serious condition. Therefore, drugs that can inhibit apoptosis in corneal endothelial cells represent an effective strategy. Simvastatin is widely used as a specific inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase, can reduce levels of low density lipoprotein (LDL) cholesterol, and exerts anti-inflammatory effects. However, the protective effect of simvastatin on corneal endothelial cells remains unclear. Therefore, the aim of this study was to elucidate whether UVB promotes the initiation of apoptosis in corneal endothelial cells and injury reversible by simvastatin treatment. Methods: We detected the cell viability, subG1 population, and caspase-3 activity. Results: Results showed that simvastatin alleviates UVB-induced cell death, cell apoptosis, and caspase-3 activity. Conclusion: Our findings indicated that simvastatin alleviated UVB-induced corneal endothelial cell apoptosis via caspase-3 activity.

Indexed as

AnimalsApoptosisCattleCell CountCells, CulturedCorneal Endothelial Cell LossEndothelium, CornealHydroxymethylglutaryl-CoA Reductase InhibitorsRadiation Injuries, ExperimentalSimvastatinUltraviolet RaysHydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinApoptosiscaspase-3 activitycorneal endothelium cellssimvastatinultraviolet B

Identifiers

PMID30038146
PMCPMC6080451
OpenAlexW2883031943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.